5.8 Pharmacopoeial Harmonisation Fixed

While not as famous as a blockbuster drug or a breakthrough therapy, is the unsung hero of the global pharmaceutical supply chain. It is the administrative and technical bridge connecting three distinct regulatory worlds.

The PDG is the primary engine behind these harmonization efforts. Its goal is to reduce the burden on manufacturers by ensuring that a single test procedure or standard can satisfy multiple regulatory jurisdictions. 5.8 pharmacopoeial harmonisation

When a text has undergone this process, Chapter 5.8 specifies how this is signaled to the user: While not as famous as a blockbuster drug

This section applies to all drug substances (DS), excipients, and drug products (DP) intended for markets where the pharmacopoeias of the Pharmacopoeial Discussion Group (PDG) – namely the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP), and the United States Pharmacopeia (USP) – are legally recognised. It also considers convergence with additional pharmacopoeias where applicable (e.g., Indian Pharmacopoeia, Chinese Pharmacopoeia). Its goal is to reduce the burden on